ARTICLE | Company News
Ligand receives approvable letter
June 12, 2000 7:00 AM UTC
LGND received an approvable letter from the FDA for Targretin bexarotene gel to treat cutaneous lesions in patients with early stage cutaneous T cell lymphoma (CTCL) who have not tolerated other thera...